title: Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
authors: Department of Interventional Radiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors: Yong-Hui
authors: YH
authors: Huang
authors: Wei
authors: W
authors: Chen
authors: Jia-Ping
authors: JP
authors: Li
authors: Bin
authors: B
authors: Chen
authors: Jian-Yong
authors: JY
authors: Yang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib